
    
      This is a prospective, multicenter, randomized, double-blind, parallel group clinical study
      to investigate the equivalence of incobotulinumtoxinA (Xeomin®) to onabotulinumtoxinA
      (Botox®) in the treatment of glabellar frown lines.
    
  